Circulating exosomes express [alpha].sub.4[beta].sub.7 integrin and compete with CD4+ T cells for the binding to Vedolizumab

Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the [alpha]4[beta]7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has show...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	PloS one 2020-11, Vol.15 (11), p.e0242342
Hauptverfasser:	Domenis, Rossana, Marino, Marco, Cifù, Adriana, Scardino, Giulia, Curcio, Francesco, Fabris, Martina, Ansari, Aftab A
Format:	Artikel
Sprache:	eng
Schlagworte:	Distribution Organelles Physiological aspects T cells Vedolizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!